BPC-157: the healing claims are ahead of the human results.
BPC-157 has a large animal literature, several small human records, a newly recruiting Phase 2 hamstring trial, and no FDA-approved drug. This guide keeps each benefits or safety claim beside the exact study, result status, and evidence limit.
There is human exposure. There is not yet proven healing efficacy.
FDA reviewed five small, short human records and concluded that the available clinical safety information is insufficient to characterize the safety profile of BPC-157 free base or BPC-157 acetate. It also found insufficient evidence for ulcerative colitis.
A separate Phase 2 hamstring-strain study first posted in February 2026 is recruiting 120 estimated participants. It has no posted results. That is a meaningful research milestone, but it does not yet establish a benefit.
Read the BPC-157 record in four fields.
This is a sourced status snapshot, not a safety score, treatment recommendation, or seller certification. Each field links back to the detailed record below.
Recruiting Phase 2
A 120-participant hamstring-strain study is recruiting. It has no posted results.
Inspect the human evidenceHealing efficacy not proven
Small human records and animal findings do not establish a healing benefit in people.
Audit the popular claimsNo FDA-approved product
A compounding review or advisory discussion is not approval of a finished drug.
Check status and destination routesDated US price boards
Identity, animal findings, human studies, and approval are different records.
The useful question is not whether a paper exists. It is what was studied, in whom, by which route, against what comparator, with which result, and whether that result has been published.
One short name can hide different forms
PubChem identifies a 15-amino-acid BPC-157 record. FDA evaluates BPC-157 free base and BPC-157 acetate separately and reports inconsistent commercial naming. A BPC-157 label alone does not establish the exact substance, salt, formulation, purity, or product.
A large animal literature is not a human result
FDA reviewed nonclinical pharmacology involving gastrointestinal, hepatic, fistula, tendon, and other models. The agency also found important gaps in dose-response, molecular targets, mechanism, toxicology, and route-specific characterization.
Small studies, one old unresolved trial, one new Phase 2 trial
FDA summarized five small, short clinical studies with limited safety reporting. The older Phase 1 registry has unknown status and no results. A 120-participant Phase 2 hamstring trial is recruiting and has no results, so it cannot yet establish healing benefit.
No FDA-approved BPC-157 drug
FDA says neither reviewed form is a component of an FDA-approved drug and staff proposed not adding either to the 503A Bulks List. On July 23, PCAC recommended inclusion after reported 8-6-1 votes on the paired form questions. That advice is nonbinding, not approval, and not a final FDA determination.
What the BPC-157 record shows, and what it cannot prove.
Each row separates a real evidence signal from the conclusion that the current record cannot support.
BPC-157 heals tendons or muscle injuries
Animal and laboratory studies report repair-related signals. NCT07437547 is a randomized Phase 2 hamstring-strain study with estimated enrollment of 120.
The Phase 2 record is recruiting and has no posted results. Preclinical findings and a trial registration do not prove faster healing, return to sport, or safety in people.
BPC-157 treats gut disease or ulcerative colitis
FDA found one small exploratory ulcerative-colitis trial described in a meeting abstract plus short rectal-enema safety and pharmacokinetic records.
FDA concluded that the available data do not support BPC-157 for ulcerative colitis. The record lacks the detail, scale, duration, and route-specific evidence needed for a treatment claim.
BPC-157 relieves knee pain or speeds recovery
FDA identified a retrospective knee-pain chart review involving 17 subjects and one or two intra-articular administrations.
An uncontrolled retrospective record cannot separate treatment effect from selection, co-interventions, natural recovery, placebo effects, or incomplete outcome reporting.
BPC-157 has no side effects
Short studies reported no serious adverse events, and a two-person pilot reported no adverse effects. FDA also found sparse adverse-event reports with major interpretation limits.
Small, short, uncontrolled studies cannot establish routine or rare event rates, long-term safety, immunogenicity, product quality, or safety across oral, subcutaneous, nasal, and transdermal routes.
Four records that answer four different questions.
Estimated enrollment is not completed enrollment. A study record is not a result. No reported adverse events in two people is not a population safety profile.
Acute grade II hamstring strain
- Design
- Phase 2, randomized, double-blind, placebo-controlled
- Participants
- 120 estimated
This is the first current controlled efficacy record for a popular healing claim. Until results are posted and evaluated, registration shows a question being tested, not a benefit.
Safety and pharmacokinetics in healthy participants
- Design
- Phase 1, randomized, oral, single and repeated dose
- Participants
- 42 estimated
The registry was last updated in 2015. Estimated enrollment and completion dates do not prove that the study finished or that unpublished safety or pharmacokinetic results exist.
Intravenous safety pilot
- Design
- Open pilot with short laboratory and vital-sign monitoring
- Participants
- 2 adults
No adverse effects were reported in two prior users over a very short observation. That finding is too small to estimate common, rare, delayed, route-specific, or product-quality risks.
Five small clinical records summarized together
- Design
- Rectal, intra-articular, intravesical, and intravenous records
- Participants
- Small and short-duration studies
FDA found limited safety monitoring, no serious events in the cited studies, headache and flatulence in rectal-enema abstracts, and insufficient information to characterize the overall safety profile.
The July 23 recommendation is meaningful, but it is not approval or final action.
FDA staff analysis, committee discussion, and final agency action are three separate stages.
Do not add either BPC-157 form
FDA proposes not adding BPC-157 free base or BPC-157 acetate to the 503A Bulks List after weighing characterization, historical use, effectiveness, safety, and available alternatives.
Read the briefing →Favorable committee recommendation
PCAC recommended inclusion of both reviewed forms after reported 8-6-1 votes. The advice is nonbinding, does not approve BPC-157, and does not immediately change the 503A Bulks List.
Open the verified vote record →Final FDA determination
FDA can complete its review after considering advisory input. Until a later agency record is published, the current position must remain labeled as a staff proposal.
Track the full process →BPC-157 access and product status are local questions.
One US FDA record cannot establish product authorization, prescription status, compounding eligibility, import rules, pharmacy licensing, or seller legitimacy worldwide. Use the exact destination's official records and keep a research listing separate from a regulated medicine.
Eight BPC-157 questions, answered from the current record.
This is educational reporting, not medical advice, a prescription, or a use protocol.
What is BPC-157?
BPC-157 is a 15-amino-acid peptide commonly identified by the sequence GEPPPGKPADDAGLV. PubChem lists molecular formula C62H98N16O22 and molecular weight 1419.5. FDA separately evaluates BPC-157 free base and BPC-157 acetate and warns that inconsistent naming can obscure which substance or active moiety a product contains.
What are the proven benefits of BPC-157?
The current cited record does not establish the broad healing, gut, recovery, or wellness benefits promoted online. FDA found insufficient evidence for ulcerative colitis, and the newly recruiting Phase 2 hamstring study has no posted results. Animal findings, small uncontrolled records, and a registered trial cannot be combined into a proven human benefit.
Does BPC-157 heal tendons or muscle injuries?
Preclinical studies support a research hypothesis, but a human healing effect is not yet established. NCT07437547 is recruiting 120 participants for a placebo-controlled Phase 2 hamstring-strain trial with return-to-sport and MRI endpoints. It has no posted results, so no benefit size, durability, recurrence effect, or clinical safety conclusion can be reported.
Does BPC-157 help ulcerative colitis or gut health?
FDA reviewed one small exploratory ulcerative-colitis trial reported only in a meeting abstract and found the evidence insufficient. The agency did not identify oral, subcutaneous, nasal, or transdermal studies in people with ulcerative colitis and concluded that available data do not support BPC-157 as a treatment for that condition.
What are the side effects of BPC-157?
A reliable side-effect rate cannot be calculated from the current evidence. FDA summarized small short studies, limited safety monitoring, headache and flatulence in rectal-enema abstracts, and sparse adverse-event reports that cannot establish causality. The agency says clinical information is insufficient to characterize safety and identifies immunogenicity, aggregation, impurity, route, and product-quality concerns.
Is BPC-157 FDA approved?
No. FDA states that neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug. FDA staff proposed not adding either form to the 503A Bulks List, but PCAC recommended inclusion after reported 8-6-1 votes on July 23, 2026. The committee advice is nonbinding, does not immediately change the list, and is not FDA approval or the final agency determination.
What is the correct BPC-157 dosage?
There is no FDA-approved BPC-157 product label or established self-use dosage for the products discussed here. Doses and routes in animal work, exploratory studies, a two-person pilot, seller pages, or a trial protocol should not be converted into a personal regimen. This guide does not provide reconstitution, injection, dosing, cycling, or stacking instructions.
Can you buy BPC-157 legally in my country?
A visible seller page or shipping claim does not answer that question. Product authorization, compounding rules, prescription controls, import restrictions, pharmacy licensing, seller identity, and the exact BPC-157 form must be checked in the destination's official records. Peptide Local provides separate country, US state, Canadian province, and Australian jurisdiction maps for those checks.
A trial being registered is progress. It is not proof of benefit.
ClinicalTrials.gov records describe planned or ongoing research. Results become interpretable only after enrollment, completion, analysis, and sufficiently complete public reporting. Outcome definitions, population, comparator, missing data, adverse events, and study conduct all matter.
FDA approval, compounding eligibility, product quality, a seller listing, and a peptide's molecular identity are also separate records. None supplies an individual treatment recommendation.